Please assess the completion status of the following clinical trial:

Trial Title: Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient is male or female ≥ 18 years of age.~2. The patient presents with stable angina pectoris, or silent ischemia (positive stress test without chest pain).~3. The patient is scheduled for coronary angiography, with possible angioplasty.~4. The patient is able to tolerate dual anti-platelet therapy with aspirin and clopidogrel for a minimum of 30 days and is on those medications at the time of the PCI (clopidogrel may be administered during PCI or within 30 minutes post PCI).~5. The patient is able and willing to conform to the requirements of the study and voluntarily signs an Informed Consent.~6. The patient does not present with any form of illness or condition that in the investigator's opinion would impair the results of the study.~7. Women of child bearing potential must have a negative urine or serum pregnancy test prior to enrollment.~Exclusion Criteria:~1. Patients in cardiogenic shock.~2. Patients with acute coronary syndrome, which includes unstable angina, non-ST-elevation MI or STEMI.~3. Known history of heparin-induced thrombocytopenia.~4. Contraindication to unfractionated heparin, bivalirudin, or any anticoagulant or antithrombotic pharmacological agent.~5. Any significant medical condition, which in the investigator's opinion, may interfere with the patient's optimal participation in the study.~6. Pregnant women or nursing mothers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bivalirudin (Type: ACTIVE_COMPARATOR): Anticoagulation during percutaneous coronary intervention
- Unfractionated Heparin (Type: ACTIVE_COMPARATOR): Anticoagulation during percutaneous coronary intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).